ClinicalTrials.gg

Program

Tacrolimus

Also written as “tacrolimus”, “Advagraf” and “tacrolimus ointment”.

Its studies are mostly in Dermatitis, Atopic · Renal Insufficiency · Arthritis, Rheumatoid · Graft vs Host Disease · Lupus Nephritis, led by 17 companies.

Furthest: phase 4, since Mar 23, 2005172 company-led studies, 3 open or runningNext primary completion: Dec 2026 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Astellas Pharma1120 open or runningphase 4since Mar 23, 2005May 8, 2002none ahead
Novartis140 open or runningphase 4since Sep 27, 2005Sep 27, 2005none ahead
Veloxis Pharmaceuticals110 open or runningphase 3since Dec 19, 2008Jul 2, 2007none ahead
Pfizer60 open or runningphase 4since Sep 12, 2005Jun 30, 2004none ahead
Johnson & Johnson50 open or runningphase 4since Feb 24, 2006Feb 24, 2006none ahead
Panacea Biotec40 open or runningno phasesince Mar 2, 2010Mar 2, 2010none ahead
Chiesi Farmaceutici30 open or runningphase 4since Apr 29, 2015Apr 29, 2015none ahead
Chong Kun Dang Pharmaceutical30 open or runningphase 4since Dec 4, 2012Dec 4, 2012none ahead
Hoffmann-La Roche30 open or runningphase 4since Jun 30, 2005Jun 30, 2005none ahead
Dr. Reddy's Laboratories20 open or runningphase 1since May 26, 2010May 26, 2010none ahead
linical-korea20 open or runningphase 4since Feb 17, 2021Feb 17, 2021none ahead
lipella-pharmaceuticals-inc21 open or runningphase 2since Apr 17, 2017Apr 17, 2017none ahead
glenmark-pharmaceuticals-ltd-india10 open or runningphase 3since Nov 9, 2015Nov 9, 2015none ahead
novaliq-gmbh11 open or runningphase 2since Dec 9, 2025Dec 9, 2025Dec 2026phase 2 · NCT07285070
Sun Pharmaceutical Industries10 open or runningphase 1since Jan 28, 2009Jan 28, 2009none ahead
tff-pharmaceuticals-inc10 open or runningphase 2since Aug 11, 2022Aug 11, 2022none ahead
VIVUS11 open or runningphase 3since May 18, 2026May 18, 2026May 31, 2028phase 3 · NCT07612657

Also a collaborator on its studies: Kyowa Kirin, novotech-australia-pty-limited, parexel, achillion-a-wholly-owned-subsidiary-of-alexion, cromsource, bio-kinetic-europe-ltd, ppd-development-lp, aptuit, astellas-pharma-us-inc and basilea-pharmaceutica-international-ltd.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 44 studies since Mar 16, 2011.

  1. Oct 28, 2016Phase 2 study in Kidney TransplantationChiesi Farmaceutici · NCT02970630 · 28 enrolled · Italy
  2. Apr 17, 2017lipella-pharmaceuticals-inc's first study: phase 2 study in Cystitis, HemorrhagicNew to lipella-pharmaceuticals-inclipella-pharmaceuticals-inc · NCT03129126 · 13 enrolled · United States
  3. Feb 21, 2018Phase 4 study in Kidney TransplantationAstellas Pharma · NCT03465969 · 80 enrolled · France, United Kingdom
  4. Aug 22, 2018Phase 4 study in Kidney TransplantAstellas Pharma · NCT03644485 · 284 enrolled · China
  5. Nov 8, 2018Phase 4 study in Arthritis, RheumatoidAstellas Pharma · NCT03737708 · 21 enrolled · Korea, Republic of
  6. Jan 3, 2019Phase 4 study in Kidney TransplantChong Kun Dang Pharmaceutical · NCT03794492 · 169 enrolled · Korea, Republic of
  7. Jun 5, 2019Phase 1 study in Kidney TransplantNovartis · NCT03978494 · France, Germany
  8. Aug 28, 2019Phase 4 study in Kidney TransplantChong Kun Dang Pharmaceutical · NCT04102943 · 128 enrolled · South Korea
  9. Feb 17, 2021linical-korea's first studies: 2 phase 4 studiesNew to linical-korealinical-korea · NCT04763096, NCT04761731
  10. Nov 29, 20212 phase 4 studies in Liver TransplantationAstellas Pharma · NCT05152628, NCT05153915
  11. Aug 11, 2022tff-pharmaceuticals-inc's first study: phase 2 study in Lung Transplant RejectionNew to tff-pharmaceuticals-inctff-pharmaceuticals-inc · NCT05501574 · 14 enrolled · Australia
  12. Dec 19, 2023Phase 2 study in Lichen Planus, Orallipella-pharmaceuticals-inc · NCT06233591 · 24 enrolled · United States
  13. Dec 9, 2025novaliq-gmbh's first study: phase 2 study in Non-infectious Anterior UveitisNew to novaliq-gmbhnovaliq-gmbh · NCT07285070 · 20 enrolled · United States
  14. May 18, 2026VIVUS's first study: phase 3 study in Pulmonary Arterial HypertensionNew to VIVUSVIVUS · NCT07612657 · 300 planned

Ahead

  1. Dec 2026Primary completion: phase 2 study in Non-infectious Anterior Uveitisnovaliq-gmbh · NCT07285070
  2. May 31, 2028Primary completion: phase 3 study in Pulmonary Arterial HypertensionVIVUS · NCT07612657

TargetBeta

FKBP1A →read by rule
“FK506-binding protein 1A inhibitor”ChEMBL 37, by rule

Other programs on FKBP1A

ProgramCompanyFurthest phaseStudies
EverolimusruleNovartisphase 4131

Studies

The newest 60 of 172 led by companies developing it. Each opens its study page. Every study on its drug page →

StudyPhaseStatusLed byPrimary completionSize
NCT07612657Pulmonary Arterial Hypertension3Not yet recruitingVIVUSMay 31, 2028300
NCT07285070Non-infectious Anterior Uveitis · United States2Active, not recruitingnovaliq-gmbhDec 202620
NCT06233591Lichen Planus, Oral · United States2Active, not recruitinglipella-pharmaceuticals-incJun 1, 202524
NCT05501574Lung Transplant Rejection · Australia2Terminatedtff-pharmaceuticals-incOct 29, 202414
NCT05153915Liver Transplantation · China4CompletedAstellas PharmaMar 14, 202456
NCT05152628Liver Transplantation · China4CompletedAstellas PharmaMar 6, 202455
NCT04763096Evidence of Liver Transplantation · Korea, Republic of4Completedlinical-koreaApr 2020101
NCT04761731Liver Transplantation4Completedlinical-koreaDec 14, 201731
NCT04102943Kidney Transplant · South Korea4CompletedChong Kun Dang PharmaceuticalSep 29, 2020128
NCT03978494Kidney Transplant · France, Germany1WithdrawnNovartisMay 3, 20200
NCT03794492Kidney Transplant · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJul 22, 2022169
NCT03737708Arthritis, Rheumatoid · Korea, Republic of4CompletedAstellas PharmaJun 16, 202021
NCT03644485Kidney Transplant · China4CompletedAstellas PharmaJul 15, 2022284
NCT03465969Kidney Transplantation · France, United Kingdom4CompletedAstellas PharmaSep 14, 201880
NCT03129126Cystitis, Hemorrhagic · United States2Completedlipella-pharmaceuticals-incAug 21, 202313
NCT02970630Kidney Transplantation · Italy2CompletedChiesi FarmaceuticiFeb 22, 201828
NCT02963103Kidney Transplantation · Korea, Republic of4TerminatedAstellas PharmaOct 201213
NCT02706678Renal Transplant Recipients · China4CompletedAstellas PharmaAug 1, 2012105
NCT02723591Kidney Transplantation · United States4CompletedAstellas PharmaJun 14, 2019599
NCT02660684Graft vs Host Disease · Korea, Republic of4CompletedAstellas PharmaFeb 201039
NCT02601703Dermatitis, Atopic · United States3Completedglenmark-pharmaceuticals-ltd-indiaOct 20161,110
NCT02563782Macular Degeneration · United States2WithdrawnAstellas PharmaMay 5, 20170
NCT02500212Organ or Tissue Transplant; Complications · France4CompletedChiesi FarmaceuticiJun 201675
NCT02457221Lupus Nephritis · China3CompletedAstellas PharmaSep 10, 2018314
NCT02432833Kidney Failure, Chronic · Italy4CompletedChiesi FarmaceuticiJan 24, 2017428
NCT02432053Kidney Transplantation · India4CompletedAstellas PharmaMay 201392
NCT02339246Renal Insufficiency · United States3CompletedVeloxis PharmaceuticalsMar 201532
NCT02268201Kidney Transplant Recipients · China4TerminatedAstellas PharmaMar 31, 201517
NCT02217410Kidney Transplantation · United States, Brazil, Germany and more2CompletedNovartisNov 29, 201759
NCT02161237Kidney Transplantation · Korea, Republic of, Taiwan4CompletedAstellas PharmaDec 22, 201673
NCT02118896Heart Transplantation · United States, Australia, Austria and more3CompletedAstellas PharmaOct 7, 2009850
NCT02115113Liver Transplantation · Italy3CompletedNovartisSep 30, 201678
NCT02034747Kidney Transplant · South Korea4CompletedAstellas PharmaNov 7, 2015150
NCT01962922Renal Insufficiency · United States3CompletedVeloxis PharmaceuticalsJul 201550
NCT01882322de Novo Liver Transplant Subjects · Korea, Republic of4CompletedAstellas PharmaJan 3, 201736
NCT01839929Kidney Transplantation · Korea, Republic of4CompletedAstellas PharmaFeb 2013138
NCT01843348Rejection, Psychology · France, Germany3CompletedNovartisMar 23, 2016612
NCT01828879Dermatitis, Atopic · Vietnam4CompletedJohnson & JohnsonJun 200974
NCT01782729Dermatitis, Atopic · Vietnam4CompletedJohnson & JohnsonNov 200830
NCT01780844Kidney Transplantation · United States2CompletedAstellas PharmaJun 30, 2014149
NCT01763580Nephrosis, Lipoid · Korea, Republic of4CompletedAstellas PharmaMay 2, 2017144
NCT01745159Lymphoma, Follicular · China4CompletedAstellas PharmaNov 2013125
NCT01746680Arthritis, Rheumatoid · Korea, Republic of4CompletedChong Kun Dang PharmaceuticalJun 2015111
NCT01742676Renal Transplantation · Korea, Republic of4CompletedAstellas PharmaApr 2013100
NCT01742624de Novo Kidney Transplantation · Korea, Republic of4CompletedAstellas PharmaJun 201260
NCT01681134Healthy · Canada1CompletedAstellas PharmaOct 201219
NCT01666951Renal Insufficiency · United States2CompletedVeloxis PharmaceuticalsMar 201336
NCT01649427Graft vs Host Disease · Germany4CompletedNovartisAug 20, 201573
NCT01614665Heart Transplantation · Czechia, France, Italy and more2CompletedAstellas PharmaApr 21, 202144
NCT01535547Pharmacokinetics of Isavuconazole · United States1CompletedAstellas PharmaJan 201224
NCT01511003Arthritis, Rheumatoid · Korea, Republic of4CompletedAstellas PharmaMay 11, 2015128
NCT01479881Hepatitis C · Belgium1CompletedJohnson & JohnsonDec 201129
NCT01438710Renal Insufficiency · United States3CompletedVeloxis PharmaceuticalsAug 201244
NCT01430065Pharmacokinetics of ASP015K · United States1CompletedAstellas PharmaJun 200924
NCT01371344Heart Transplantation · Belgium, France, Germany and more4TerminatedAstellas PharmaApr 2, 201747
NCT01371331Kidney Transplantation · Belgium, France, Germany and more4CompletedAstellas PharmaFeb 3, 201552
NCT01342016Lupus Nephritis · China3TerminatedAstellas PharmaMay 201384
NCT01339468Liver Transplantation · Korea, Republic of4CompletedAstellas PharmaMay 27, 2014100
NCT01332201Heart Transplantation · Austria, Belgium, France and more2CompletedAstellas PharmaNov 201317
NCT01325571Myasthenia Gravis · China3CompletedAstellas PharmaMay 201483

How it is read

Names in the registry

  • “Tacrolimus”, 50 entries
  • “tacrolimus”, 26 entries
  • “Advagraf”, 12 entries
  • “tacrolimus ointment”, 9 entries
  • “Prograf”, 7 entries

Codes read as this program: LP10, FK506E, FK506MR.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.